Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

C H A P T E R 4FINANCIAL ASPECTSFINANCIAL RESOURCES ANDEXPENDITURESWHO’s official financial budgeting and reporting is doneon a biennial basis. During the biennium 2002–2003,specified contributions amounting to US$ 5 942 816were received by WHO for GPELF. The total carry-overfrom 2001 was US$ 2 403 824. Funds in the amount ofUS$ 4 014 052 were obligated from the grant from the Billand Melinda Gates Foundation. A total of US$ 1 019 180was obligated from the grant made by the Departmentfor International Development of the United Kingdom.Funds in the amount of US$ 70 034 were obligated fromthe Australian Agency for International Development.A total of US$ 335 033 was obligated from the grant fromthe Arab Fund for Economic and Social Development.Funds to the amount of US$ 90 424 were obligated fromGSK’s contribution of US$ 176 610 during the bienniumof 2002–2003. Merck & Co., Inc. contributed a total ofUS$ 122 000 of which US$ 110 621 was obligated.All figures are provisional and WHO will release auditedfinancial figures for the 2002–2003 biennium.The estimated cost to protect an at-risk individual variesbetween US$ 0.07 and US$ 0.15. The estimated costof GPELF is US$ 1 billion over the next 15 years. Forthe biennium 2004–2005 an estimated US$ 70 millionis required to protect 350 million people by the end of2005.WAYS AND MEANS OF ACHIEVINGTARGETSGAELF must continue to generate political commitmentat national, regional and local levels and muststrengthen awareness of the importance of supportingthe vital efforts being made to cover all at-risk populationsin endemic countries. To accomplish this, nationaland local authorities in the endemic countries mustassume direct responsibility for their own LF eliminationprogrammes.GPELF benefits from the support of the partners of GAELF.GSK has made a commitment to make albendazole availablefree of charge until LF is eliminated. Merck & Co.,Inc. expanded the MDP for onchocerciasis to cover thecountries co-endemic with LF and targeted for MDA in allof the African countries where the diseases coexist. Partnersfrom the public sector (such as the Department forInternational Development of the United Kingdom and theMinistry of Health and Social Welfare of Japan), from theprivate sector (such as the Bill and Melinda Gates Foundation),and from academia (such as the Liverpool LF SupportCentre) have provided funds to initiate and continueboth global and national programmes.Members of GAELF will seek the necessary additionalfunding from bilateral agencies and private sourceseven while making special efforts to access availableInternational Financial Institutions/World Bank fundsthat could be quickly applied to GPELF activities.DEPARTMENT FOR INTERNATIONALDEVELOPMENT OF THE UNITEDKINGDOMDFID is responsible for promoting development andreducing poverty worldwide. The current goal of DFIDis to assist the effort to reduce by half the proportionof people living in extreme poverty by 2015. Parallelobjectives are providing basic health care and accessto primary education for all by the same date. DFIDseeks to work in partnership with governments, business,civil society and the research community committedto these targets. It also works with multilateralinstitutions such as the World Bank, United Nationsspecialized agencies including WHO, and the EuropeanCommunity.In August 1999, DFID made its first contribution to theWHO PELF and has continued to be a generous donorto the programme since that date. In 2003, as a result offunding from DFID, WHO accomplished the following:• fostering of additional private–public and countrypartnerships;• formulation of technical and policy guidelines andassessment of national programmes through TAG-LFand the RPRGs;• TAG-LF and RPRG meetings;• technical and financial support to regions and countries;117Annual Report on Lymphatic Filariasis 2003Chapter 4 Financial aspects